News
GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...
In older patients with cancer and type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with ...
For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs).
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
HealthDay on MSN16h
GLP-1 Receptor Agonist Use in T2D Tied to Increased Risk for GERD, GERD ComplicationsFor patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased ...
USA: Researchers have found in a new study that patients with idiopathic intracranial hypertension (IIH) treated with ...
GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...
Researchers have determined in a new study that the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower the risk of ...
Glucagon-like peptide 1 receptor agonist (GLP-1 RA) therapy in idiopathic intracranial hypertension is associated with significant reductions in medication use, symptoms/signs, and procedural ...
NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
LA-GLP1 RA Effects on the Risk of Medullary Thyroid Cancer GLP-1 receptors are present in several tissues including the pancreas, intestine, stomach, nervous system and others.
A Trump administration proposal to consider another form of drugs for Medicare price cuts is spurring legal and policy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results